SPECT Radiopharmaceuticals

  • Vikas Tandon
  • Nadine Gauthier
  • Terrence D. Ruddy
Chapter

Abstract

Over the last century, radiopharmaceuticals have been used extensively in the diagnosis and treatment of various diseases. In cardiology, their main application is for the diagnosis and prognosis of coronary artery disease (CAD). Myocardial perfusion imaging allows the visualization of myocardium via the use of radiotracers. The most common tracers used in SPECT imaging are Thallium-201 (201Tl) and Technetium-99m (99mTc) labeled compounds.

Keywords

Ischemia Attenuation Radionuclide Thallium Technetium 

References

  1. 1.
    Baggish AL, Boucher CA. Radiopharmaceutical agents for myocardial perfusion imaging. Circulation. 2008;118:1668–74.PubMedCrossRefGoogle Scholar
  2. 2.
    Cerqueira MD, et al. Recommendations for reducing radiation exposure in myocardial perfusion imaging. J Nucl Cardiol. 2010;17:709–18.PubMedCrossRefGoogle Scholar
  3. 3.
    Fazel R. ASNC statement: strategies for defining an optimal risk-benefit ratio for stress myocardial perfusion SPECT. J Nucl Cardiol. 2011;18:385–92.PubMedCrossRefGoogle Scholar
  4. 4.
    Henzlova MJ, et al. ASNC imaging guidelines: stress protocols and tracers. J Nucl Cardiol. 2009;10:25–37.Google Scholar
  5. 5.
    Libby P, Bonow RO. Braunwald’s heart disease – a textbook of cardiovascular medicine. 8th ed. St. Louis: Saunders; 2007.Google Scholar

Copyright information

© Springer-Verlag London 2013

Authors and Affiliations

  • Vikas Tandon
    • 1
  • Nadine Gauthier
    • 2
  • Terrence D. Ruddy
    • 2
  1. 1.St. Josephs Healthcare HamiltonHamiltonCanada
  2. 2.Division of CardiologyUniversity of Ottawa Heart InstituteOttawaCanada

Personalised recommendations